Adial Pharmaceuticals
ADIL • NASDAQ
Adial Pharmaceuticals is a biotechnology company in the healthcare sector trading on NASDAQ, led by CEO Cary John Claiborne, with a market cap of $2.3M.
CEOCary John Claiborne
Next Earnings
Upcoming earnings announcement for Adial Pharmaceuticals
Date
Thursday, May 14, 2026 (in a month)
Timing
Before Market Open (8:00 AM New York)
Fiscal Period
Q1 2026
EPS Estimate
-$2.06
Earnings History
Past 12 earnings reports for Adial Pharmaceuticals
| Date | Period | EPS | EPS Surprise | Revenue | Rev. Surprise | Filing |
|---|---|---|---|---|---|---|
| Mar 6, 2026 | Q4 2025 | -$11.48Est: -$2.12 | -441.5% | - | — |  10-K |
| Nov 13, 2025 | Q3 2025 | -$0.08Est: -$0.11 | +27.3% | - | — | 10-Q |
| Aug 13, 2025 | Q2 2025 | -$0.18Est: -$0.22 | +18.2% | - | — | 10-Q |
| May 15, 2025 | Q1 2025 | -$0.34Est: -$0.50 | +32.0% | - | — | 10-Q |
| Mar 4, 2025 | Q4 2024 | -$0.15Est: -$0.33 | +54.5% | - | — | 10-K |
| Nov 13, 2024 | Q3 2024 | -$0.38Est: -$0.41 | +7.3% | - | — | 10-Q |
| Aug 13, 2024 | Q2 2024 | -$0.59 | — | - | — | 10-Q |
| May 14, 2024 | Q1 2024 | -$2.19Est: -$0.35 | -525.7% | - | — | 10-Q |
| Apr 1, 2024 | Q4 2023 | -$0.37Est: -$0.47 | +21.3% | - | — | — |
| Nov 14, 2023 | Q3 2023 | -$1.14Est: -$1.13 | -0.9% | - | — | — |
| Aug 21, 2023 | Q2 2023 | -$1.33Est: -$1.50 | +11.3% | - | — | 10-Q |
| May 12, 2023 | Q1 2023 | -$2.75Est: -$3.50 | +21.4% | - | — | — |